Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?

Diabetes, Obesity and Metabolism

Volumn 19, Issue 6, 2017, Pages 909-911

  Goncalves, Edison ^a   Bell, David S H ^b  

^a Diabetes Thyroid Associates   (United States)

^b Southside Endocrinology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; EMPAGLIFLOZIN; HEMOGLOBIN A1C; LIRAGLUTIDE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; BODY MASS; CARDIOVASCULAR RISK; DIABETES MELLITUS; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; LETTER; WEIGHT REDUCTION; AGED; AGONISTS; ANTAGONISTS AND INHIBITORS; BLOOD; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; BENZHYDRYL COMPOUNDS; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 85014677689     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12897     Document Type: Letter

References (13)

1. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18(3):203-216.
2. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009;11(2):79-88.
3. Bain S, Druyts E, Balijepalli C, et al. Cardiovascular events and all-cause mortality associated with sulfonylureas compared with other antihyperglycaemic drugs: a bayesian meta-analysis of survival data. Diabetes Obes Metab. 2016; doi:10.1111/dom.12821. [Epub ahead of print].
4. Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004-1016.
5. Bell DS. The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss. Am J Case Rep. 2014;15:152-154.
6. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(5):457-466.
7. Thomas L, Grempler R, Eckhardt M, et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab. 2012;14(1):94-96.
8. Salsali A, Kim G, Woerle HJ, Broedl UC, Hantel S. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. Diabetes Obes Metab. 2016;18(10):1034-1040.
9. Holst JJ, Christensen M, Lund A, et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab. 2011;13(suppl 1):89-94.
10. Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB. Liraglutide: short-lived effect on gastric emptying – long lasting effects on body weight. Diabetes Obes Metab. 2012;14(6):531-538.
11. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-124.
12. Plutzky J, Garber A, Falahati A, Toft AD, Poulter NR. Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis. Can J Diabetes. 2009;33(3):209-210.
13. Ariel D, Kim SH, Abbasi F, Lamendola CA, Liu A, Reaven GM. Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutr Metab Cardiovasc Dis. 2014;24(12):1317-1322.